Anti-PD-1 Therapy

The ASCO press releases have begun; first up to the plate is BMS and their anti-PD-1 antibody. Similar to ipilimumab, this drug works through immune system checkpoint modulation.In other words, it works by releasing the natural inhibition of our immune system, hopefully allowing our long rumored immune system’s ability to fight cancer to actually be effective.

Three papers on anti-PD-1 therapy for melanoma and other cancers, as well as another immunotherapy paper about tumor infiltrating lymphocytes, will be presented at a Developmental Therapeutics session on Saturday, June 2 at ASCO at 1:15 pm.

Press release-based write-ups already on the web:



(NEJM article to be released same day)

  • Share this post:
  • Facebook
  • Twitter
  • Delicious
  • Digg
Shopping Cart (0 Items)
Your cart is empty!

Subtotal: $0.00
Total: $0.00